Bitcoin (BTC) has been trading below the psychologically critical $100,000 level for the past few days, signaling a lack of ...

Biogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of its blockbuster spinal muscular atrophy (SMA) drug Spinraza.

SMA-50 Crossed Above SMA-20 Stocks- 50 day moving avergae above 20 day moving average: The primary application of Simple Moving Average is for analyzing stock trends Multiply the power of your ...

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are now reviewing the ... The announcement marks a potential advancement for SMA care and has been positively ...

Bitcoin (BTC) has been quiet over the weekend, indicating that the bulls and the bears are waiting for the next trigger to ...

Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) ...

Now, the CHMP has backed conditional approval of Zolgensma for babies and young children with SMA, which could lead to full EMA approval within the next couple of months. Novartis says it will ...

and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen comprises a ...

在人类的5号染色体上，有一个名叫SMN1的基因，它的存在是决定人体合成SMN蛋白的关键。SMN蛋白对运动神经元的存活至关重要，如果SMN蛋白不足，那么就会导致运动神经元逐渐退化并死亡，反映到机体上也就引起肌肉无力和萎缩。